Aligos Therapeutics (ALGS) EBIT (2019 - 2026)

Aligos Therapeutics (ALGS) has reported EBIT for 8 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 89.82% year-over-year to -$1.9 million; the trailing twelve-month figure through Jun 2026 stood at -$79.0 million (down 0.62% YoY), and the FY2025 full-year result was -$88.0 million, up 1.31% from the prior year.
• EBIT advanced to -$1.9 million in Q2 2026 per ALGS's latest filing, from -$26.9 million in the prior quarter.
• Across five years, EBIT topped out at -$1.9 million in Q2 2026 and bottomed at -$35.6 million in Q1 2022.
• Historically, EBIT has averaged -$21.8 million across 5 years, with a median of -$21.2 million in 2024.
• The sharpest annual moves came in 2025 and 2026: EBIT slumped 40.88% in 2025, then soared 89.82% in 2026.
• Over 5 years, EBIT stood at -$22.7 million in 2022, then decreased by 14.62% to -$26.0 million in 2023, then gained by 20.9% to -$20.6 million in 2024, then declined by 6.08% to -$21.8 million in 2025, then surged by 91.34% to -$1.9 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$1.9 million, -$26.9 million, and -$21.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.